- Home
- BB vs DAWN Comparison
BB vs DAWN Comparison
Compare BB & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BB | DAWN |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BB | DAWN |
|---|---|---|
| Price | $3.56 | $21.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $4.90 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 7.9M | 3.4M |
| Earning Date | 04-09-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.91 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $534,900,000.00 | $158,182,000.00 |
| Revenue This Year | $4.19 | $55.03 |
| Revenue Next Year | $7.63 | $28.12 |
| P/E Ratio | $69.20 | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $2.81 | $5.64 |
| 52 Week High | $5.32 | $21.47 |
Technical Indicators
Market Signals| Indicator | BB | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 60.82 | 81.65 |
| Support Level | $3.55 | $10.30 |
| Resistance Level | $3.59 | N/A |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.04 | -0.34 |
| Stochastic Oscillator | 93.62 | 94.74 |
Price Performance
Historical ComparisonAbout BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.